Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome (Q38978503)

8 September 2017

1 reference

title

Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome (English)

1 reference

8 September 2017

arterial hypertension

0 references

1 reference

1 reference

Sundararajan Srikanth

series ordinal

1

1 reference

PubMed ID

27730495

8 September 2017

Prakash Deedwania

series ordinal

2

1 reference

8 September 2017

1 October 2016

1 reference

Current Hypertension Reports

8 September 2017

1 reference

8 September 2017

18

1 reference

8 September 2017

10

1 reference

8 September 2017

76

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-016-0683-0

8 September 2017

0 references

cites work

Remnant lipoproteins and atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Remnant cholesterol as a causal risk factor for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Immunity, atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Update on acute coronary syndromes: the pathologists' view

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Inactivating mutations in NPC1L1 and protection from coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Ph

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effects of extended-release niacin with laropiprant in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Enalapril attenuates oxidative stress in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Role of the renin-angiotensin- aldosterone system in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Treatment of obesity in 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Statins for people at low risk of cardiovascular disease – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Mediterranean Diet Inversely Associated With the Incidence of Metabolic Syndrome: The SUN prospective cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-016-0683-0

Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine

21 January 2018

1 reference

12 December 2020

Metabolic benefits associated with sibutramine therapy

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Small LDL, atherogenic dyslipidemia, and the metabolic syndrome

1 reference

12 December 2020

Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.

1 reference

12 December 2020

Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)

1 reference

12 December 2020

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

12 December 2020

Enalapril and losartan attenuate mitochondrial dysfunction in aged rats

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S11906-016-0683-0

Identifiers

DOI

1 reference

PubMed ID

27730495

Dimensions Publication ID

8 September 2017

0 references

1 reference

PubMed ID

27730495